Shulman, L. N., Cirrincione, C. T., Berry, D. A., Becker, H. P., Perez, E. A., O'Regan, R., . . . Hudis, C. (2012). Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. American Society of Clinical Oncology.

Shulman, Lawrence N., et al. Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. American Society of Clinical Oncology, 2012.

Shulman, Lawrence N., et al. Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101. American Society of Clinical Oncology, 2012.